• HOME PAGE
  • ABOUT US
  • OUR TEAM
    • Doctors
    • Nurses
    • Laboratory Technicians
    • Public Relations
    • Support Staff
  • OUR SERVICES
    • Cancer Diagnosis and Treatment
    • Laboratory Services
    • Nursing Services
  • ARTICLES
    • New Developments in Cancer Treatment
    • New Developments in Lung Cancer Treatment
    • New Developments in Early-Stage Breast Cancer Treatment
    • New Developments in the Treatment of Metastatic Breast Cancer
    • New Developments in Colon Cancer Treatment
    • New Developments in Pancreatic Cancer Treatment
    • New Developments in Prostate Cancer Treatment
  • TANSAN IN THE PRESS
  • EVENTS & DEVELOPMENTS
  • VIDEOS
  • CONTACT
+90 212 225 27 56
  • Home
  • New Developments in Lung Cancer Treatment

New Developments in Lung Cancer Treatment

New Developments in Lung Cancer Treatment

Lung cancer treatment has changed considerably in recent years. Alongside the stage of the disease, we can now look more closely at the characteristics of cancer cells to guide care. The starting point is an accurate pathological diagnosis, careful staging and assessment by a multidisciplinary team. Small-cell and non-small-cell lung cancers require different approaches, and the patient’s general health and priorities also shape the plan. [1] For non-small-cell lung cancer, molecular testing is an important part of choosing treatment. Changes in genes such as EGFR, ALK, ROS1, RET, MET, BRAF, HER2 and KRAS may open the way to targeted medicines for suitable patients. PD-L1 testing can also inform immunotherapy decisions. These tests answer different questions; interpreting them together helps identify an appropriate treatment from the outset. [1] Surgery remains central to operable disease. For selected patients, adding immunotherapy to chemotherapy before surgery and continuing immunotherapy afterwards can reduce the risk of recurrence. The 2026 AEGEAN update supports this approach. In inoperable stage III disease, osimertinib has become an option for patients with certain EGFR mutations whose cancer has not progressed after chemoradiotherapy, extending the time it remains under control without progression. [2,3] Targeted treatments for advanced disease continue to develop. In 2026, sevabertinib received accelerated US approval as an initial treatment for advanced non-small-cell lung cancer with certain HER2 mutations. Also published in 2026, the Krascendo 1 trial showed that divarasib provided longer disease control than the earlier-generation medicines studied in previously treated patients with KRAS G12C mutations. A positive trial result does not, by itself, mean a medicine is routinely available in every country. [4,5] Antibody–drug conjugates offer another approach to delivering chemotherapy. Datopotamab deruxtecan received accelerated US approval for advanced EGFR-mutated disease after EGFR-directed treatment and platinum chemotherapy. Its antibody carries a chemotherapy drug towards a specific target on cancer cells, although careful monitoring for side effects remains essential. [6] There has also been progress in small-cell lung cancer. Durvalumab after chemoradiotherapy can extend survival in limited-stage disease that has not progressed. In extensive-stage disease progressing after platinum chemotherapy, tarlatamab is a bispecific antibody that brings immune cells and cancer cells together. The 2026 DeLLphi-305 trial reported improved survival when tarlatamab was added to durvalumab maintenance for patients without progression after initial chemotherapy and immunotherapy, highlighting a new maintenance strategy. [7–9] These advances do not make one treatment right for everyone. Their value lies in bringing current evidence together with the individual patient’s circumstances, discussing potential benefits, side effects and access in Türkiye, and choosing a plan that also takes everyday life into account. Sources [1] NCI · NSCLC | [2] AEGEAN · 2026 | [3] LAURA · NEJM | [4] HER2 · 2026 | [5] Krascendo 1 · 2026 | [6] FDA · ADC | [7] ADRIATIC · NEJM | [8] DeLLphi-304 · NEJM | [9] DeLLphi-305 · 2026

Molecular investigations are an important part of treatment selection in non-small cell lung cancer. Investigating changes in genes such as EGFR, ALK, ROS1, RET, MET, BRAF, HER2 and KRAS can pave the way for targeted therapies in suitable patients. PD-L1 investigation also helps in the decision-making process for immunotherapy. These tests are not interchangeable; evaluating the results together ensures that the correct option is chosen at the beginning of treatment. [1]

While surgery retains its importance in surgically treatable disease, adding immunotherapy to preoperative chemotherapy and continuing immunotherapy after surgery in selected patients can reduce the risk of disease recurrence. The 2026 update of the AEGEAN study supports this approach. In inoperable stage III disease, osimertinib has taken its place as an option to prolong the time the disease remains under control without progression in individuals with specific EGFR mutations who do not progress after chemoradiotherapy. [2,3]

Targeted therapies continue to develop in advanced stages. For example, in 2026, sevabertinib received accelerated approval in the US as the first-line treatment option for advanced non-small cell lung cancer carrying certain HER2 mutations. Also in 2026, the Krascendo 1 study showed that divarasib provided longer disease control than previous generation drugs compared in previously treated patients with KRAS G12C mutations. This new research result does not mean that it will be available for routine use in every country. [4,5]

Antibody-mediated chemotherapies are also among the new options. Datopotamab deruxtecan, an antibody drug conjugate, is one of the treatments that received accelerated approval in the US after chemotherapy targeting EGFR and platinum. The aim here is to deliver chemotherapy to a specific target in the tumor cell; however, monitoring for side effects is still necessary. [6]

There is also progression in small cell lung cancer. In individuals with limited-stage disease that does not progress after chemoradiotherapy, durvalumab can prolong survival. Tarlatamab, used in advanced-stage disease that progresses after platinum-based treatment, is a dual-specific antibody that brings immune cells and cancer cells together. The 2026 DeLLphi-305 study reported improved survival when tarlatamab was added to durvalumab in individuals with no disease progression after initial chemotherapy and immunotherapy; this result suggests a new maintenance therapy approach. [7–9]

All these options do not mean that the same treatment is suitable for every patient. The main goal is to combine current information with the individual's situation, evaluating the expected benefits, potential side effects, and accessibility in Türkiye; and to chart a course that also considers the patient's daily life.

Sources  [1] NCI · NSCLC  |  [2] AEGEAN · 2026  |  [3] LAURA · NEJM  |  [4] HER2 · 2026  |  [5] Krascendo 1 · 2026  |  [6] FDA · ADC  |  [7] ADRIATIC · NEJM  |  [8] DeLLphi-304 · NEJM  |  [9] DeLLphi-305 · 2026

Call

Latest News & Announcements

  • Tansan Oncology Celebrates its 30th Anniversary with Pride.

    As Tansan Oncology, we are a passenger in the field of healthcare...
  • Following the Path of Scientific Progress: Participation of Our Clinical Team in the Turkish Medical Oncology Congress 2026

    Closely following the latest developments in the field of oncology...
  • We need to stop fighting death.

    Click to go to the link. He turned his pocket...
  • Müjdat Gezen wrote: Süalp Tansan | Cumhuriyet

    Click here to go to the link. Kandemir (Kond...
  • ‘'Vitamin D plays a vital role in preventing cancer!'’

    Click here to go to the link. Dr. Sualp Tansa...
  • LAW ON THE PROTECTION OF PERSONAL DATA (LPPD) INFORMATION TEXT
  • PERSONAL DATA STORAGE AND DESTRUCTION POLICY
  • POLICY ON THE PROTECTION AND PROCESSING OF SPECIAL CATEGORY PERSONAL DATA
  • DECLARATION OF EXPLICIT CONSENT UNDER THE PERSONAL DATA PROTECTION LAW (KVKK)
  • SATISFACTION SURVEY

Tansan Oncology © 03.07.2026 All rights reserved.
These articles are written for patient information purposes.

TOP
EN
TR
By continuing to use our website, our privacy policy By doing so, you agree to the use of cookies.